Mepolizumab long-term remodeling effect in severe asthma responders: the MESILICO study.

Study limitation reported by the research below: “High dropout rate from original cohort to bronchoscopy sub-study (47 → 25) likely enriches for clinical responders, which may overestimate the remodeling benefit in a real-world severe asthma population.”